Corporate Profile

Basic Information

Corporate Information [PDF: 414KB]

Company Name Mitsubishi Tanabe Pharma Corporation
Capital Stock 50 billion yen
President&Representative Director UENO Hiroaki
Headquarters 3-2-10, Dosho-machi, Chuo-ku,
Osaka 541-8505, Japan
TEL: 81-6-6205-5085
Number of Employees 6,728 (Consolidated)  3,383 (Non-consolidated)(As of March 31, 2021)
Incorporated December 13, 1933
Date of Merger October 1, 2007

Business Activities

Pharmaceuticals

Manufacture and sale of pharmaceuticals, centered on ethical drugs

Major Ethical Drugs

Central nervous system

Lexapro anti-depressant agent
Radicut (Radicava) cerebral neuroprotectant

Immuno-inflammation

Remicade agent for treatment of rheumatoid arthritis, Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, ulcerative colitis and Kawasaki disease
Simponi agent for treatment of rheumatoid arthritis and ulcerative colitis
Stelara agent for treatment of Crohn’s disease
Imusera agent for treatment of multiple sclerosis

Others

Tenelia agent for treatment of type Ⅱ diabetes mellitus
Canaglu agent for treatment of type Ⅱ diabetes mellitus
Canalia agent for treatment of type Ⅱ diabetes mellitus
Vafseo agent for treatment of renal anemia
Rupafin agent for treatment of allergic disorders

Vaccines

Influenza vaccine  
TETRABIK combined vaccine for diphtheria, pertussis, tetanus and poliomyelitis (polio)
Mearubik combined vaccine for measles and rubella
JEBIK V vaccine for Japanese encephalitis
Varicella vaccine  

Major OTC Products

  • Flucort f (agent for treatment of skin conditions)
  • Cort f series (agent for treatment of skin conditions)
  • Tanabe ichoyaku〈choritsu〉(digestive medicine)
  • Tanabe ichoyaku urso (digestive medicine)
  • Urso ukon (digestive drink)
  • Cerekinon S (digestive medicine)
  • Aspara drink α (nutrient and tonic drink)